Improving long-term outcomes for patients with liver metastases from colorectal cancer

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9063-9066

  Chong, Geoffrey ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; DRUG CLEARANCE; DRUG HALF LIFE; EDITORIAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT; ADJUVANT THERAPY; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; NOTE; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 33644824747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4669     Document Type: Editorial

References (29)

1. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1997
2. Weber SM, Jarnagin WR, DeMatteo RP, et al: Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 7:643-650, 2000
3. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001
4. Adam R: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 14:ii13-ii16, 2003 (suppl 2)
5. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1061-1064, 2004
6. Portier G, Rougier P, Milan C, et al: Adjuvant systemic chemotherapy using 5-fluorouracil and folinic acid after resection of liver metastases from colorectal origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002). Proc Am Soc Clin Oncol 20:528, 2002 (abstr)
7. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20:1499-1505, 2002
8. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999
9. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 352:734-735, 2005
10. Pozzo C, Basso M, Cassano A, et al: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933-939, 2004
11. Goldberg RM, Sargent DJ, Ivlorton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
12. Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 16:425-429, 2005
13. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX4) for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group (NCCTG) phase II study. J Clin Oncol 23:9243-9249, 2005
14. Poston GJ, Haller D, Kahan J, et al: Individualize the treatment of liver metastases from colorectal cancer using RAND appropriateness method: Oncosurge decision model-Results of a consensus detecting from the international taskforce group. J Clin Oncol 22:268, 2004 (suppl; abstr 3595)
15. Nordlinger B, Sorbye H, Debois M, et al: Feasibility and risks of pre-operative chemotherapy with Folfox 4 and surgery for resectable colorectal cancer liver metastases. Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol 23:253, 2005 (suppl; abstr 3528)
16. Chau I, Allen MJ, Cunningham D, et al: The value of routine serum carcinoembryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22:1420-1429, 2004
17. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
18. Kemeny N, Jarnagin W, Paty P, et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888-4896, 2005
19. Leonard G, Curran SD, Kemeny N, et al: A comparative assessment of the incidence of steatohepatitis seen with modern chemotherapy agents. J Clin Oncol 23:741, 2005 (suppl; abstr 8051)
20. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466, 2004
21. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
22. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1, 2005 (suppl; abstr 2)
23. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
24. Diaz Rubio E, Tabernero J, Van Cutsem E, et al: Cetuximab in combination with oxaliplatin/5-fluorouracil/folinic acid (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol 23:254, 2005 (suppl; abstr 3535)
25. Leonard GD, Brenner B, Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038-2048, 2005
26. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol 22:294, 2004 (suppl; abstr 3702)
27. Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855, 2005
28. Elias D, Baton O, Sideris L, et al: Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 90:36-42, 2005
29. Roth AD, Rubbia-Brandt L, Majno P, et al: Results of inverse strategy using systemic chemotherapy first, liver resection second, and primary tumor resection last for patients with advanced synchronous liver metastases from colorectal cancer. J Clin Oncol 23:291, 2005 (suppl; abstr 3683)